Substantial patent litigation activity occurred in the mRNA space in 2022, involving nearly all of the major mRNA and lipid nanoparticle (LNP) pioneers. Since this is the most significant happening in this space with respect...more
In the first major patent infringement lawsuit in the mRNA space, on February 28, 2022, Arbutus Biopharma Corporation (“Arbutus”) and Genevant Sciences GmbH (“Genevant”) sued Moderna, Inc. and ModernaTX, Inc. (collectively...more
In April of 2021, we provided a three-part series relating to the IP and Competitive Landscape for the mRNA market. In this post we provide a 2021 year in review update on mRNA pioneers and key players and offer additional...more
In Part I of this three-part series, we focused on three mRNA technology market players: BioNTech, Moderna and CureVac. In this second post, we will focus on Translate BIO, Arcturus Therapeutics, and eTheRNA and discuss...more
Shortly after we posted about Moderna, Inc.’s October 2020 pledge not to enforce its COVID-19-related patents during the pandemic, the United States Food & Drug Administration (FDA) granted emergency regulatory approval for...more
Moderna, one of the global leaders in developing a safe and effective vaccine to combat COVID-19, appears poised to get through clinical trials with a vaccine that is based on mRNA technology. As was recently announced,...more
11/16/2020
/ Coronavirus/COVID-19 ,
Final Written Decisions ,
Inter Partes Review (IPR) Proceeding ,
Life Sciences ,
Moderna Inc. ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Popular ,
USPTO ,
Vaccinations
Last month, Moderna Therapeutics, one of the global leaders in the race to produce a COVID-19 vaccine, made the following statement regarding enforcement of its patents:
We feel a special obligation under the current...more
11/10/2020
/ Bayh-Dole Act ,
Biotechnology ,
Coronavirus/COVID-19 ,
Department of Defense (DOD) ,
European Commission ,
Inter Partes Review (IPR) Proceeding ,
Life Sciences ,
Moderna Inc. ,
Patent Invalidity ,
Patent Ownership ,
Patents ,
Pharmaceutical Patents ,
Popular ,
Research and Development ,
USPTO ,
Vaccinations